Tasigna (nilotinib) / Novartis, Inhibikase 
Welcome,         Profile    Billing    Logout  

80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tasigna (nilotinib) / Novartis, Inhibikase
2010-023508-28: A CLINICAL TRIAL OF THE INTRA-TUMOURAL CONCENTRATION AND ACTIVITY OF NILOTINIB IN INTRA-CUTANEOUS SCHWANNOMAS

Ongoing
4
5
Europe
Capsule, Tasigna
Plymouth Hospital NHS Trust
In vivo investigation of the intra-tumoural concentration and activity of nilotinib in cutaneous schwannomas (CS) in patienst with Neurofibromatosis 2
 
 
ChiCTR-RPC-16010078: The influence of polymorphisms of metabolic enzymes and transporters on pharmacokinetics and clinical response to imatinib, dasatinib and nilotinib

Recruiting
4
450
 
The determination of concentration and genotypes ;The determination of concentration and genotypes ;The determination of concentration and genotypes
The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, raise (funds/etc.) independently
chronic myelogenous leukemia
 
 
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
2021-006581-20: A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia

Not yet recruiting
4
106
Europe
Tablet, Capsule, hard, Imatinib, SPRYCEL, Bosulif, Tasigna, Iclusig
Radboud univeristy medical centre, ZonMw
Chronic myeloid leukaemia, Blood cancers, leukaemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
SUSTRENIM, NCT02602314 / 2015-005248-33: Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

Active, not recruiting
4
450
Europe
Imatinib, Nilotinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronyc Myeloid Leukemia
02/23
02/24
NCT01735955 / 2012-003902-28: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Completed
4
57
Europe, Canada, US, RoW
Nilotinib, AMN107
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
07/23
07/23
NCT00756509 / 2008-000358-11: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Active, not recruiting
4
34
Europe
Nilotinib
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
12/24
12/24
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Asciminib, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
NCT01580059: Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Recruiting
3
300
RoW
nilotinib
King Faisal Specialist Hospital & Research Center
Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia
06/13
 
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
GRAAPH2014, NCT02611492: A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Recruiting
3
265
Europe
Nilotinib, Methotrexate, Aracytine (Ara C), Granulocyte Colony-Stimulating Factor (G-CSF), Depomedrol, Dexamethasone, Vincristine, Imatinib, 6 Mercaptopurine (6MP)
Assistance Publique - Hôpitaux de Paris
Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
12/20
12/25
ChiCTR-OCH-11001699: The comparative study of quality of life and toxisities in patients with chronic myeloid leukemia during imatinib therapy vs. nilotinib therapy

Completed
3
180
 
imatinib ;imatinib
Peking University People's Hospital, Peking University Institute of Hematology; Peking University People's Hospital, Peking University People's Hospital, Peking University Institute of Hematology
Chronic myeloid leukemia
 
 
2021-000678-27: A study to compare oral asciminib versus existing TKI medicines in patients with newly diagnosed CML Vizsgálat az orálisan alkalmazott asciminib és tirozin-kináz inhibitor (TKI) között újonnan diagnosztizált krónikus mieloid leukémiában (CML) szenvedő betegeknél

Ongoing
3
402
Europe
Asciminib, Bosulif, Glivec, Tasigna, Sprycel, ABL001, STI571, AMN107, Film-coated tablet, Capsule, hard, Bosulif, Glivec, Tasigna, Sprycel
Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients, CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells., Diseases [C] - Cancer [C04]
 
 
2022-000995-21: A study to compare asciminib versus nilotinib in patients with newly diagnosed CML Egy tanulmány az asciminib és a nilotinib összehasonlítására újonnan diagnosztizált CML-ben szenvedő betegeknél

Ongoing
3
553
Europe, RoW
Asciminib, Tasigna, ABL001, AMN107, Film-coated tablet, Capsule, hard, Tasigna
Novartis Pharma AG, Novartis Pharma AG
Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients, CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells., Diseases [C] - Cancer [C04]
 
 
NCT03942094: Nilotinib for First-line Newly Diagnosed CML-CP Patients

Recruiting
3
100
RoW
Nilotinib
Shenzhen Second People's Hospital, Zhongshan City People's Hospital, The Affiliated Hospital of Guangdong Medical College, Huazhong University of Science and Technology Union Shenzhen Hospital, Dongguan People's Hospital, Longgang District Central Hospital of Shenzhen
Chronic Myeloid Leukemia, Chronic Phase, Nilotinib
06/23
12/23
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
ASC4FIRST, NCT04971226 / 2021-000678-27: A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Asciminib, ABL001
Novartis Pharmaceuticals, Novartis Pharma AG
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
11/23
01/28
OPTKIMA, NCT02326311: Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Recruiting
3
502
Europe
imatinib, Glivec, nilotinib, Tasigna, dasatinib, Sprycell
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Leukemia, Chronic Myeloid
12/23
12/23
NILEAD, NCT05143528: Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

Not yet recruiting
3
1275
NA
Nilotinib BE 84mg, Nilotinib BE 112 mg, Placebo
KeifeRx, LLC, Worldwide Clinical Trials, Life Molecular Imaging GmbH, Sun Pharmaceuticals Industries Limited
Alzheimer Disease
12/25
06/26
ASC4START, NCT05456191: A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Recruiting
3
550
Europe, Canada, US, RoW
Asciminib, ABL001, Nilotinib
Novartis Pharmaceuticals
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
02/27
03/27
2014-002146-44: Blood cancer in younger adults (18-59 years) Cancer du sang de l'adulte jeune (18-59 ans)

Ongoing
2/3
1040
Europe
Atriance, Tasigna, cyclophosphamide, méthotrexate, vincristine, cytarabine, Etoposide, dexamethasone, prednisone, 6-mercaptopurine, daunorubicine, idarubicine, L-Asparaginase, G-CSF, imatinib, BLINATUMOMAB, Nélarabine, Nilotinib, Solution for infusion, Capsule, Powder for injection, Solution for injection, Tablet, Powder for infusion, Powder and solvent for solution for injection, Powder for concentrate and solution for solution for infusion, Atriance, Tasigna, cyclophosphamide, méthotrexate, vincristine, cytarabine, Etoposide, dexamethasone, prednisone, 6-mercaptopurine, daunorubicine, idarubicine, L-Asparaginase, G-CSF, imatinib, Blincyto
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Patients with de novo acute lymphoblastic leukemia of young adults. -GRAALL-2014/B: Ph- B lineage ALL -GRAALL-2014/T et ATRIALL: T-ALL -GRAAPH-2014: ALL Ph+ Patients présentant une Leucémie Aigue Lymphoblastique de l'adulte jeune de novo. -GRAALL-2014/B : LAL de la lignée B Ph- -GRAALL-2014/T et ATRIALL : LAL T -GRAAPH-2014 : LAL Ph+, Acute Lymphoblastic Leukemia Leucémie Lymphoblastique Aigüe, Diseases [C] - Cancer [C04]
 
 
ACTRN12612000019808: Evaluation of the efficacy of nilotinib in the treatment of patients with pigmented villo-nodular synovitis / tenosynovial giant cell tumour

Not yet recruiting
2
50
 
Centre Leon Berard, Novartis
Pigmented villo-nodular synovitis, Tenosynovial giant cell tumour
 
 
NCT01207492: Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Active, not recruiting
2
17
US
nilotinib
Andrew J. Wagner, MD, PhD, Brigham and Women's Hospital, Massachusetts General Hospital, Novartis
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
04/14
01/25
2012-004048-31: Multicenter single-arm pilot study evaluating efficacy of nilotinib in CML patients with molecular relapse after Glivec discontinuation within the context of the STIM trials (STIM and STIM2), Nilo Post-STIM Etude pilote prospective destinée à évaluer l'efficacité du nilotinib chez des patients atteints de leucémie myéloïde chronique (LMC) présentant une rechute moléculaire après l'arrêt de l'imatinib (essais STIM [Stop Imatinib]), Nilo Post-STIM

Ongoing
2
70
Europe
Tasigna, AMN107, Capsule, Nilotinib, Tasigna®, 150 mg, Nilotinib, Tasigna®, 200 mg
CHU de Bordeaux, PHAO 2012, Novartis
Chronic myeloid leukemia (CML) Leucémie myéloïde chronique (LMC), Diseases [C] - Cancer [C04]
 
 
ChiCTR-ONC-12002469: Therapeutic Effect and Safety Study of Nilotinib plus chemotherapy in de novo Ph+ Acute Lymphoblastic Leukemia Patients

Recruiting
2
30
 
Nilotinib plus chemotherapy
Hospital of Blood Diseases, Chinese Academy of Medical Sciences; Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Novartis
De novo Ph+ Acute Lymphoblastic Leukemia
 
 
ENESTop, NCT01698905 / 2012-003186-18: Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib

Active, not recruiting
2
163
Europe, Canada, Japan, US, RoW
nilotinib, AMN107
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
11/15
01/25
2009-013271-22: Front-line treatment of Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) with two tyrosine kinase inhibitors (TKI) (Imatinib and Nilotinib). A phase II exploratory multicentric study in elderly patients and in patients unfit for program of intensive therapy and allogeneic stem cell transplantation

Ongoing
2
40
Europe
TASIGNA*28CPS 200MG, GLIVEC*24CPS 100MG, TASIGNA*28CPS 200MG, GLIVEC*24CPS 100MG
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL, ADULTO
Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL)
 
 
2010-022713-26: Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at least 1 year of adjuvant imatinib mesylate

Ongoing
2
73
Europe
Tasigna 200 mg Hartkapseln, Tasigna 200 mg Hartkapseln
Novartis Pharma GmbH
localized gastrointestinal stromal tumors (GIST)
 
 
2012-005062-34: An open label, single arm, phase II study of nilotinib 300 mg BID in newly diagnosed CP-CML patients, in order to verify disappearance of CD34+/lin-Ph+ cells from bone marrow during treatment. Studio non randomizzato di fase II con Nilotinib 300 mg BID in pazienti con nuova diagnosi di leucemia mieloide cronica (LMC) in fase cronica, al fine di verificare la scomparsa delle cellule CD34+/lin-Ph+ midollari durante il trattamento

Ongoing
2
87
Europe
TASIGNA*112CPS 150MG, TASIGNA*112CPS 150MG
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA\' GRANDA (A.O. DI RILIEVO NAZIONALE), REL Niguarda Novartis
newly diagnosed CP-CML patients pazienti con nuova diagnosi di leucemia mieloide cronica (LMC) in fase cronica
 
 
ENESTFreedom, NCT01784068 / 2012-004092-40: Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Active, not recruiting
2
215
Europe, Japan, US, RoW
Nilotinib followed by treatment-free, AMN107
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
05/16
02/25
ACTRN12612000851864: Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response

Active, not recruiting
2
100
 
Australasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group
chronic myeloid leukaemia
 
 
2018-001843-29: Trial to investigate if the addition of novel agents in combination with TKI can improve response compared to TKI alone in patients with TKI resistant chronic myeloid leukaemia.

Not yet recruiting
2
102
Europe
Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib, Tazemetostat, EPZ-6438, Film-coated tablet, Capsule, hard
NHS Greater Glasgow and Clyde, University of Glasgow, , Cancer Research UK, Epizyme
Chronic myeloid leukaemia, Chronic myeloid leukaemia, Diseases [C] - Cancer [C04]
 
 
2018-002256-33: Asciminib combination in chronic phase CML

Not yet recruiting
2
155
Europe
Asciminib-Hydrochlorid, Nilotinib (Hydrochlorid-Monohydrat), Dasatinib (Monohydrat), Imatinib (Mesilat), ABL001, AMN107, Film-coated tablet, Capsule, hard, Tasigna, Sprycel, all Imatinib (Mesilat) proprietary medicinal products with a marketing authorisation in Germany can be used in this clinical trial, Scemblix
Friedrich-Schiller-Universität Jena, Novartis Pharma GmbH
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Active, not recruiting
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
NCT01863745: Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Completed
2
15
Japan
nilotinib
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
10/23
10/23
TOKIN, NCT04626024: Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

Recruiting
2
100
US
Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation, Gleevec, Sprycel, Tasigna, Bosulif
Baylor College of Medicine
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
11/25
11/25
NCT04002674: Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Recruiting
2
60
US
Placebo oral capsule, Placebo, Nilotinib Oral Capsule, Tasigna
Georgetown University, National Institutes of Health (NIH)
Dementia With Lewy Bodies
12/23
12/23
ECOG-ACRIN EA9171, NCT03516279: Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Recruiting
2
40
US
Dasatinib, BMS-354825, Sprycel, Imatinib Mesylate, CGP 57148, CGP57148B, Gleevec, Glivec, STI 571, STI-571, STI571, Laboratory Biomarker Analysis, Nilotinib, AMN 107, Tasigna, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
08/28
08/31
S1712, NCT03654768: Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Active, not recruiting
2
84
US
Bosutinib, Bosulif, SKI 606, SKI-606, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Laboratory Biomarker Analysis, Nilotinib, AMN107, NILOTINIB HYDROCHLORIDE MONOHYDRATE, Nilotinib Monohydrochloride Monohydrate, Tasigna, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Imatinib, Gleevec®, STI-571
SWOG Cancer Research Network, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
07/24
07/28
NCT04449549: Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Recruiting
2
34
US
Nilotinib and Paclitaxel
National Cancer Institute (NCI)
Neoplasms
04/25
04/25
PEARL, NCT06409936: Study: PotEntial of Asciminib in the eaRly Treatment of CML

Not yet recruiting
2
160
NA
Asciminib, Nilotinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia
09/28
09/31
HQP1351CC203, NCT04126681: A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Active, not recruiting
2
144
RoW
HQP1351, Hydroxyurea or Interferon-based therapy, Homoharringtonine, Imatinib, Dasatinib or Nilotinib
Ascentage Pharma Group Inc., HealthQuest Pharma Inc.
Chronic Myeloid Leukemia, Chronic Phase
12/24
12/25
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting
2
900
Europe
Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab
Centre Leon Berard, National Cancer Institute, France
Malignant Solid Neoplasms
01/26
10/27
READIT, NCT04578847: A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Active, not recruiting
2
100
RoW
Imatinib, Nilotinib, Dasatinib, Bosutinib
National Research Center for Hematology, Russia
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia
01/25
01/25
ALERTCML, NCT05143840: Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Recruiting
2
8
US
Asciminib, ABL001, Ascimininb + Nilotinib, ABL001 + TASIGNA, Asciminib + Imatinib, ABL001 + Gleevec, Asciminib + Dasatinib, ABL001 + Sprycel
Augusta University, H. Jean Khoury Cure CML Consortium
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
02/25
02/27
NCT05554341: Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Suspended
2
40
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nilotinib Hydrochloride Monohydrate, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
07/25
07/25
HALF, NCT04147533: Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia

Active, not recruiting
2
150
RoW
Imatinib withdrawal, Glivec withdrawal, Dasatinib, Sprycel withdrawal, Nilotinib, Tasigna withdrawal
Masaryk University
Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug
06/26
06/26
DANTE, NCT03874858 / 2018-002898-21: De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination

Active, not recruiting
2
124
Europe
Nilotinib, AMN107, Asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
11/26
12/26
NAUT, NCT02917720 / 2015-004998-33: 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

Active, not recruiting
2
75
Europe
TKI discontinuation, nilotinib
European LeukemiaNet, Heidelberg University, Ludwig-Maximilians - University of Munich
Chronic Myeloid Leukemia
09/26
09/27
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
CMLXI, NCT03906292: Frontline Asciminib Combination in Chronic Phase CML

Active, not recruiting
2
125
Europe
Imatinib, Imatinib 400 mg QD and asciminib 60 mg QD, Nilotinib 300 mg, Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD, Dasatinib, Dasatinib 100 mg QD and asciminib 80 mg QD, Asciminib
University of Jena, Ludwig-Maximilians - University of Munich, Novartis Pharmaceuticals
Chronic Myeloid Leukemia
12/27
12/27
NCT04838041: Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Recruiting
2
51
US
Asciminib 40 MG, ABL001, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Gleevec, Nilotinib, TASIGNA, Dasatinib, Sprycel
Medical College of Wisconsin, H. Jean Khoury Cure CML Consortium
Chronic Phase Chronic Myelogenous Leukemia
06/28
07/29
NCT05185947: Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Recruiting
2
70
US
Paclitaxel, Nilotinib
National Cancer Institute (NCI)
Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms
12/28
12/31
NCT05564377: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
2
2900
US
Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Ipatasertib, GDC-0068, RG-7440, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Neratinib Maleate, 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx, Nilotinib Hydrochloride Monohydrate, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
07/30
07/30
NCT01746836: Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recruiting
2
50
US
Laboratory Biomarker Analysis, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
12/30
12/30
KRT-232-117, NCT04835584 / 2020-004699-16: KRT-232 and TKI Study in Chronic Myeloid Leukemia

Recruiting
1b/2
109
Europe, Canada, US, RoW
KRT-232, Dasatinib, Dasatinib Zentiva, Nilotinib, Tasigna
Kartos Therapeutics, Inc.
Chronic Myeloid Leukemia
12/24
06/26
2016-005214-21: Clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study Ensayo Clínico de ruxolitinib en combinación con nilotinib y prednisona para mielofibrosis: Estudio RuNiC

Ongoing
1/2
44
Europe
Jakavi, prednisone, Tablet, Capsule, Jakavi, Tasigna
Grupo Español de Enfermedades Mieloproliferativas GEMFIN, Grupo Español de Enfermedades Mieloproliferativas Crónicas Filadelfia Negativas, GEMFIN
Myeloproliferative Diseases Enfermedades mieloproliferativas, Myelofibrosis Mielofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-000899-28: A clinical trial evaluating vildagliptin and nilotinib as a combination treatment to achieve and succesfully maintain treatment free remission in patients with chronic myeloid leukemia. Een klinisch onderzoek naar vildagliptine en nilotinib als combinatiebehandeling voor het bereiken en handhaven van behandelingsvrije remissie bij patiënten met chronische myeloïde leukemie.

Ongoing
1/2
20
Europe
Nilotinib, Vildaglipitin, AMN107, Capsule, Tablet, Tasigna, Galvus
Albert Schweitzer Hospital, Albert Schweitzer Hospital
Chronic myeloid leukemia Chronische myeloïde leukemie, Chronic myeloid leukemia is a disease of the stem cells in the bone marrow. The abnormal stem cell multiplies and mature and develop into near-normal white cells . Chronische myeloïde leukemie is een ziekte van stamcellen in het beenmerg. De kern van een stamcel is beschadigd geraakt en dat zorgt ervoor dat witte bloedcellen in het beenmerg zich te snel delen., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ChiCTR-ONC-10000894: Nilotinib plus multi-agent chemotherapy for philadelphia chromosome-positive acute lymphoblastic leukemia

Recruiting
1
30
 
Nilotinib plus multi-agent chemotherapy
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences; Novartis pharmaceutical co., Ltd, Novartis pharmaceutical co., Ltd
Philadelphia chromosome-positive acute lymphoblastic leukemia
 
 
NCT01407198: Nilotinib With Radiation for High Risk Chordoma

Active, not recruiting
1
29
US
Nilotinib, AMN 107, Tasigna, Radiation therapy, External beam radiation
Massachusetts General Hospital
Chordoma
02/16
12/25
CABL001X2101, NCT02081378: A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Completed
1
326
Europe, Japan, US, RoW
Asciminib (ABL001), ABL001, Nilotinib, Imatinib, Dasatinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
06/21
03/23
NCI-ALMANAC, NCT02379416: Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Recruiting
1
70
US
Nilotinib + Paclitaxel
National Cancer Institute (NCI)
Solid Tumors
12/24
12/24
NCT04205903: Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Recruiting
1
20
US
Nilotinib, AMN 107 Base Form, Nilotinib Hydrochloride Monohydrate, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Placebo, placebo therapy, PLCB, sham therapy, Questionnaire Administration
Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/24
01/24
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Recruiting
1
15
US
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib
Ruta Arays, Novartis, National Cancer Institute (NCI)
Metastatic Melanoma, BRAF Gene Mutation
12/26
03/27
NCT00302016 / 2005-001818-41: Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No Longer Available
N/A
US, Canada, Europe, RoW
AMN107
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
11/08
 
NCT00413270: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

No Longer Available
N/A
Canada
nilotinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
 
 
NCT01549548: Compassionate Use Ponatinib

No Longer Available
N/A
US
Ponatinib, AP24534
OHSU Knight Cancer Institute, Ariad Pharmaceuticals
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
 
 
CML0912, NCT01699217: Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

Active, not recruiting
N/A
127
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Phase Philadelphia Positive, BCR-ABL Positive, Chronic Myeloid Leukaemia
12/17
12/22
NCT04498871: MAP to Provide Access to Nilotinib, for Patients With HES

No Longer Available
N/A
NA
Nilotinib
Novartis Pharmaceuticals
Hypereosinophilic Syndrome (HES)
 
 
NCT04326933: Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Active, not recruiting
N/A
40
RoW
Tyrosine kinase Inhibitors (Imatinib & Nilotinib), Glivic & Tasigna
Assiut University
Patients Diagnosed as Chronic Meyloid Leukemia
02/22
03/22
NCT04559555: MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

No Longer Available
N/A
NA
Nilotinib
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL)
 
 
NOFRETETE, NCT05734053: Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line

Completed
N/A
222
Europe
Nilotinib, Tasigna
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
09/22
09/22
NCT05743465: A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Completed
N/A
1769
US
No Intervention
Takeda
Leukemia
11/22
11/22
NCT04518644: Nilotinib, for Patients With CML-CP or CML-AP

No Longer Available
N/A
NA
Nilotinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML)
 
 
NCT01316250: Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Recruiting
N/A
25
RoW
Nilotinib, Tasigna, Gleevec
American University of Beirut Medical Center
Chronic Myelogenous Leukemia
07/25
07/25
FINESTdm, NCT04681820: Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

Recruiting
N/A
200
RoW
Flumatinib, Nilotinib
Wuhan Union Hospital, China
CML-CP; Mutation;Suboptimal Response or Failure in TKI
12/23
11/24
TIKlet, NCT01860456: TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The Study

Recruiting
N/A
412
Europe
Imatinib/Nilotinib, Gleevec, Tasigna
University of Pisa
Chronic Myeloid Leukemia
12/24
12/24
HS-2020-07SZ, NCT04739826: Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Recruiting
N/A
491
RoW
Flumatinib Mesylate, Nilotinib Pill
The First Affiliated Hospital of Soochow University
CML, Chronic Phase; TKI
01/25
12/25
ChiCTR2300067576: A prospective, multicenter clinical study of Nilotinib in pediatric patients with chronic myeloid leukemia in chronic phase

Not yet recruiting
N/A
100
 
Nilotinib Capsules
The First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital, Sun Yat-Sen University, Self-financing
Chronic myeloid leukemia
 
 

Download Options